TuisALMKT • EPA
add
Mauna Kea Technologies SA
Vorige sluiting
€0,19
Dagwisseling
€0,18 - €0,19
Jaarwisseling
€0,16 - €0,53
Markkapitalisasie
12,00 m EUR
Gemiddelde volume
121,80 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(EUR) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 2,13 m | -40,22% |
Bedryfskoste | 3,51 m | -5,78% |
Netto inkomste | -2,34 m | -267,42% |
Netto winsgrens | -109,77 | -380,03% |
Wins per aandeel | — | — |
EBITDA | -1,76 m | -559,07% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(EUR) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 3,82 m | -39,56% |
Totale bates | 18,15 m | -25,14% |
Totale aanspreeklikheid | 38,49 m | -5,23% |
Totale ekwiteit | -20,34 m | — |
Uitstaande aandele | 64,62 m | — |
Prys om te bespreek | -0,60 | — |
Opbrengs op bates | -25,45% | — |
Opbrengs op kapitaal | -56,78% | — |
Kontantvloei
Netto kontantverandering
(EUR) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -2,34 m | -267,42% |
Kontant van bedrywe | -1,90 m | -233,29% |
Kontant van beleggings | 36,50 k | 183,91% |
Kontant van finansiering | -226,50 k | -218,90% |
Netto kontantverandering | -2,09 m | -232,96% |
Beskikbare kontantvloei | -802,94 k | -487,16% |
Meer oor
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Gestig
2000
Webwerf
Werknemers
65